Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study.

Dierynck I, Thys K, Ghys A, Sullivan JC, Kieffer TL, Aerssens J, Picchio G, De Meyer S.

J Infect Dis. 2014 Dec 15;210(12):1871-80. doi: 10.1093/infdis/jiu340. Epub 2014 Jun 18.

PMID:
24943725
[PubMed - in process]
2.

Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.

Susser S, Vermehren J, Forestier N, Welker MW, Grigorian N, Füller C, Perner D, Zeuzem S, Sarrazin C.

J Clin Virol. 2011 Dec;52(4):321-7. doi: 10.1016/j.jcv.2011.08.015. Epub 2011 Sep 15.

PMID:
21924672
[PubMed - indexed for MEDLINE]
3.

In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir.

Jiang M, Mani N, Lin C, Ardzinski A, Nelson M, Reagan D, Bartels D, Zhou Y, Nicolas O, Rao BG, Müh U, Hanzelka B, Tigges A, Rijnbrand R, Kieffer TL.

Antimicrob Agents Chemother. 2013 Dec;57(12):6236-45. doi: 10.1128/AAC.01578-13. Epub 2013 Oct 7.

PMID:
24100495
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.

De Meyer S, Dierynck I, Ghys A, Beumont M, Daems B, Van Baelen B, Sullivan JC, Bartels DJ, Kieffer TL, Zeuzem S, Picchio G.

Hepatology. 2012 Dec;56(6):2106-15. doi: 10.1002/hep.25962.

PMID:
22806681
[PubMed - indexed for MEDLINE]
5.

Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.

Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J, Jiang M, Adiwijaya B, Ghys A, Beumont M, Kauffman RS, Adda N, Jacobson IM, Sherman KE, Zeuzem S, Kwong AD, Picchio G.

PLoS One. 2012;7(4):e34372. doi: 10.1371/journal.pone.0034372. Epub 2012 Apr 12.

PMID:
22511937
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevir.

Thomas XV, de Bruijne J, Sullivan JC, Kieffer TL, Ho CK, Rebers SP, de Vries M, Reesink HW, Weegink CJ, Molenkamp R, Schinkel J.

PLoS One. 2012;7(7):e41191. doi: 10.1371/journal.pone.0041191. Epub 2012 Jul 27.

PMID:
22848441
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1.

Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2013 Jun;85(6):1028-36. doi: 10.1002/jmv.23579.

PMID:
23588728
[PubMed - indexed for MEDLINE]
8.

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.

Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD.

Gastroenterology. 2007 May;132(5):1767-77. Epub 2007 Feb 21.

PMID:
17484874
[PubMed - indexed for MEDLINE]
9.

Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.

Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, Tigges AM, Ghys A, Dorrian J, Adda N, Martin EC, Beumont M, Jacobson IM, Sherman KE, Zeuzem S, Picchio G, Kieffer TL.

Clin Infect Dis. 2013 Jul;57(2):221-9. doi: 10.1093/cid/cit226. Epub 2013 Apr 10.

PMID:
23575197
[PubMed - indexed for MEDLINE]
Free Article
10.

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.

Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S.

Hepatology. 2007 Sep;46(3):631-9.

PMID:
17680654
[PubMed - indexed for MEDLINE]
11.

Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy.

Trimoulet P, Pinson P, Papuchon J, Foucher J, Vergniol J, Chermak F, Wittkop L, Castaing N, Merrouche W, Reigadas S, Molimard M, Kann M, Fleury H, de Lédinghen V.

Antivir Ther. 2013;18(5):723-7. doi: 10.3851/IMP2632. Epub 2013 May 23.

PMID:
23702639
[PubMed - indexed for MEDLINE]
12.

Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo.

Hiraga N, Imamura M, Abe H, Hayes CN, Kono T, Onishi M, Tsuge M, Takahashi S, Ochi H, Iwao E, Kamiya N, Yamada I, Tateno C, Yoshizato K, Matsui H, Kanai A, Inaba T, Tanaka S, Chayama K.

Hepatology. 2011 Sep 2;54(3):781-8. doi: 10.1002/hep.24460. Epub 2011 Aug 2.

PMID:
21626527
[PubMed - indexed for MEDLINE]
13.

Incidence of virological failure and emergence of resistance with twice-daily vs every 8-h administration of telaprevir in the OPTIMIZE study.

Dierynck I, Ghys A, Witek J, Luo D, Janssen K, Daems B, Picchio G, Buti M, De Meyer S.

J Viral Hepat. 2014 Dec;21(12):835-42. doi: 10.1111/jvh.12347.

PMID:
25402544
[PubMed - in process]
14.

Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection.

Akuta N, Suzuki F, Fukushima T, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.

J Clin Microbiol. 2014 Jan;52(1):193-200. doi: 10.1128/JCM.02371-13. Epub 2013 Nov 6.

PMID:
24197875
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.

Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, Hughes E, Ralston R, Tong X, Herrmann E, Zeuzem S, Sarrazin C.

Hepatology. 2009 Dec;50(6):1709-18. doi: 10.1002/hep.23192.

PMID:
19787809
[PubMed - indexed for MEDLINE]
16.

Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C virus subgenotype 1a-infected patients from Manitoba.

Andonov A, Kadkhoda K, Osiowy C, Kaita K.

Can J Gastroenterol. 2013 Jul;27(7):414-6.

PMID:
23862174
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.

Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong AD, Picchio G, Kieffer TL.

J Virol. 2013 Feb;87(3):1544-53. doi: 10.1128/JVI.02294-12. Epub 2012 Nov 14.

PMID:
23152524
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

[Telaprevir resistance].

Poveda E, García F.

Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:26-32. doi: 10.1016/S0213-005X(13)70121-6. Review. Spanish.

PMID:
24063900
[PubMed - indexed for MEDLINE]
19.

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.

Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Watahiki S, Miyakawa Y, Kumada H.

J Clin Virol. 2012 Aug;54(4):352-4. doi: 10.1016/j.jcv.2012.04.024. Epub 2012 Jun 1.

PMID:
22658798
[PubMed - indexed for MEDLINE]
20.

Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.

Aherfi S, Solas C, Motte A, Moreau J, Borentain P, Mokhtari S, Botta-Fridlund D, Dhiver C, Portal I, Ruiz JM, Ravaux I, Bregigeon S, Poizot-Martin I, Stein A, Gérolami R, Brouqui P, Tamalet C, Colson P.

J Med Virol. 2014 Nov;86(11):1868-76. doi: 10.1002/jmv.24016. Epub 2014 Jul 23.

PMID:
25052594
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk